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Introduction
Diffuse large B- cell lymphoma (DLBCL) is the most com-
mon type of lymphoma in the Western World [1]. Despite 
improved treatment with immunochemotherapy, 30% of 
the patients are refractory to treatment or relapse after 
initial response to treatment [2]. The variable outcomes 
of DLBCL could, at least partially, be explained by the 
genetic heterogeneity of DLBCL, which is increasingly 
recognized in the 2016 revision of the World Health 
Organization classification of lymphoid neoplasms [3]. In 
particular, cell of origin (activated B- cell [ABC] versus 
germinal center B- cell [GCB] phenotype and chromosomal 
translocations involving MYC and BCL2 or/and BCL6 
(double/triple hit) are considered highly relevant for prog-
nosis [3]. The differences in the molecular genetics of 
the ABC and GCB subtypes of DLBCL provide rationale 
for differential use of novel drugs and may be exploited 
in future DLBCL treatment [4]. However, despite advances 
in the understanding of molecular genetics of DLBCL, 
R- CHOP (rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone) or similar therapies remain 
the standard treatment for DLBCL and clinical prognostic 
scores still weigh heavily in treatment decisions [5]. The 
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Abstract
The international prognostic index (IPI) and similar models form the corner-
stone of clinical assessment in newly diagnosed diffuse large B- cell lymphoma 
(DLBCL). While being simple and convenient to use, their inadequate use of 
the available clinical data is a major weakness. In this study, we compared 
performance of the International Prognostic Index (IPI) and its variations (R- 
IPI and NCCN- IPI) to a Cox proportional hazards (CPH) model using the 
same covariates in nondichotomized form. All models were tested in 4863 newly 
diagnosed DLBCL patients from population- based Nordic registers. The CPH 
model led to a substantial increase in predictive accuracy as compared to con-
ventional prognostic scores when evaluated by the area under the curve and 
other relevant tests. Furthermore, the generation of patient- specific survival curves 
rather than assigning patients to one of few predefined risk groups is a relevant 
step toward personalized management and treatment. A test- version is available 
on lymphomapredictor.org.
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international prognostic index (IPI), developed almost 
25 years ago, was the first widely accepted prognostic 
score for aggressive lymphomas. The IPI sums a number 
of individual risk factors (lactate dehydrogenase [LDH] 
>upper normal limit, age at diagnosis >60 years, Ann 
Arbor stage III or IV disease, Eastern Oncology Cooperative 
Group [ECOG] performance score >1, and >1 extranodal 
site) with equal weight in a total score ranging from 0 
to 5. Patients are then assigned to four prognostic sub-
groups with different outcomes: low (score 0–1), 
intermediate- low (2), intermediate- high (3), and high- risk 
disease (4–5) [6]. Population- based studies and clinical 
trial data have confirmed the robustness of the IPI despite 
treatment changes over time [2, 7]. Modified versions of 
the IPI with fewer prognostic subgroups or more variables 
have been proposed over the years [7–9]. Simplicity of 
clinical prognostic scores was required for use at the time 
they were developed, but more complex prognostic models 
with better utilization of data are relevant alternatives 
with today’s widespread availability of mobile devices. 
Previous studies in medicine have shown that dichotomiz-
ing continuous variables leads to a substantial loss of 
model performance [10, 11]. In this study, we show how 
outcome prediction in DLBCL is substantially improved 
by a Cox proportional hazards (CPH) model assuming 
linearity for continuous covariates.
Methods
Patients
This study was based on the nationwide Danish (LYFO) 
and Swedish (SLR) lymphoma registers, which contain 
detailed information on baseline clinicopathologic features, 
treatment, and outcome of lymphoma patients in both 
countries. As a rule, variables are entered prospectively 
by local hematology departments and the coverage relative 
to the national pathology or cancer registers is 98% for 
LYFO and 95% for SLR [12, 13]. Both registers are peri-
odically merged with the national civil registers, which 
contain the dates of death of all deceased inhabitants. 
Reporting of relapse/progression to LYFO is mandatory 
and safeguarding measures against missing registrations 
include merging with the national Danish Pathology and 
the National Danish Patient Registries (which contains 
information on hospital reimbursements).
The inclusion criteria in this study were (1) newly 
diagnosed DLBCL between 1 January 2006 and 31 
December 2014 for the Danish cohort and between 01 
July 2007 and 31 December 2013 for the Swedish cohort 
(2) no CNS (parenchymal, leptomeningeal, and/or intra-
vitreal) involvement at baseline, (3) full treatment infor-
mation and treated with R- CHOP, R- CHOEP, or R- CEOP 
therapy, (4) age ≥ 18 years, and (5) full information on 
all IPI variables and LDH levels. Inclusion criterion (1) 
was necessary to ensure the availability of countrywide 
LDH reference levels.
Prognostic models
We compared the model with continuous variables to 
the IPI, Revised IPI (R- IPI), and National Comprehensive 
Cancer Network IPI (NCCN- IPI). The R- IPI was devel-
oped by analyzing rituximab- treated patients from British 
Columbia (Canada) and consists of a regrouping of the 
IPI- score into only three risk groups: low (0), intermedi-
ate (1–2), and high risk (3–5) [6]. A more recent and 
refined IPI variation, the NCCN- IPI, introduced incre-
mental scores for increasing age and normalized LDH 
ratio (measured LDH divided by the upper normal level). 
To accomplish this, the cut- points for the effect of age 
at diagnosis and normalized LDH ratio were chosen based 
on a Cox proportional hazards (CPH) model with cubic 
spline effects [9]. This led to the categorization of age 
into the following categories: <=40 (score 0), 41–60 (1), 
61–75 (2), and >75 (3). The normalized LDH ratio was 
categorized as ≤1 (0), 1–3 (1), and >3 (2). Furthermore, 
involvement of more than one extranodal site as a risk 
factor was replaced by the involvement of at least one 
of the following sites: lungs, bone marrow, liver/gastro-
intestinal tract, and/or central nervous system. The 
dichotomization of the Ann Arbor stage and ECOG per-
formance status remained as in the IPI. The resultant 
NCCN- IPI score ranges from 0 to 8 and patients are 
categorized into the risk groups low (0–1), low- 
intermediate (2–3), high- intermediate (4–5), and high 
(6–8) [9].
Statistics
The overall survival (OS) was measured as the time from 
diagnosis until death from any cause. Patients still alive 
in May 2016 (LYFO) and April 2015 (SLR) were censored. 
The regression model under investigation was a CPH 
model including the same variables as the IPI. Logarithmic 
transformation of the normalized LDH ratio was performed 
to avoid overly large and influential values. The effects 
of age, normalized LDH ratio, and number of extranodal 
sites were modeled as continuous linear effects, whereas 
ECOG performance and Ann Arbor stage were included 
as categorical. Country- specific survival curves according 
to the IPI, R- IPI, and NCCN- IPI were obtained using 
the Kaplan–Meier estimator. Finally, to inspect loss of 
information caused by variable dichotomizing in the IPI, 
five additional Cox models, each with one dichotomized 
variable, were tested.
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Comparisons of different prognostic models were per-
formed by estimating different performance measures by 
repeated 10- fold cross validation in the Danish cohort. 
Furthermore, to test the generalizability of the model obtained 
from the Danish cohort, the Swedish cohort was used as 
an external validation set. Overall model performance of 
the different models was summarized using the time- varying 
area under the curve (AUC), the C- index, and the integrated 
Brier score (IBS). The AUC at time t summarizes how well 
the risk score discriminates between being alive, Y(i) = 1, 
or dead, Y(t) = 0, at time t [14]. The C- index summarizes 
the time- varying AUC over time. It measures the probability 
of a patient having a higher risk score than a second patient 
given that the first patient died earlier [15]. The Brier score 
at time t measures the squared prediction error between 
the predicted probabilities, S(t), of being alive at time t 
and the observed status of the patients at time t, that is, 
(Y(t)–S(t))^2 [16, 17]. The IBS is the integral of the Brier 
score over a prespecified time interval and summarizes the 
predictive power of the survival model in this interval. For 
the IBS and the C- index, a cut- off point of 7.5 years was 
used. To measure the capability of the CPH model to iden-
tify high- risk patients, we explored whether the CPH model 
could identify patients with a predicted 2- year survival of 
less than 50%, as models capable of this have been called 
for and represents an unmet need in prognostic modeling 
[9]. The positive predictive values (PPV) are then an esti-
mate of the proportion of deaths in the high- risk group 
[18]. Calculations were performed in R version 3.4.1 [19]. 
The IBSs were obtained using the “pec” package version 
2.5.3, the C- indices from the “survC1” package version 1.0- 
2, and the time- varying AUCs, and PPVs from the “tim-
eROC” package version 0.3 [20–22].
Results
In total, 2696 and 2167 DLBCL patients were included 
from the LYFO and the SLR, respectively. Relative to the 
population sizes, fewer Swedish patients than expected 
were included as a result of missing information on criti-
cal baseline characteristics and treatment information in 
the surveyed period (Fig. S1, flow chart). Summaries of 
patient characteristics are shown in Table 1. Patients 
included from the SLR generally had lower Ann Arbor 
stage, fewer extranodal sites involved, and a higher fre-
quency of elevated LDH as compared to Danish patients. 
Differences in extranodal site involvement may be explained 
by structural differences in the registers, that is, more 
anatomic sites are by default registered in the Danish 
register. Differences in the frequencies of Ann Arbor stages 
may be explained by the use of Musshoff stage in the 
SLR, which may represent cases that would have been 
diagnosed as stage IV in LYFO.
The median follow- up was 5.5 years in the Danish 
cohort and 4.8 years in the Swedish cohort. The 5- year 
OS probabilities among Danish and Swedish patients were 
0.67 (0.65; 0.69) and 0.68 (0.66; 0.70), respectively. The 
NCCN- IPI, R- IPI, and IPI specific OS curves were esti-
mated using the Kaplan–Meier method (Fig. 1). The 
NCCN- IPI identified a group of patients with a 2- year 
OS <50%, but this was not the case for the IPI and 
R- IPI (Fig. 1).
The hazard ratios (HR) from the CPH model obtained 
from the Danish data are shown in Table 2. When using 
the original IPI model as reference, the added predictive 
performance for each of the performance indices of the 
CPH model was more than twice the magnitude of the 
added predictive value of the NCCN- IPI. The C- index 
was highest for the CPH model (C- index 0.73), which 
implies that the order of the risk scores of the CPH 
model was closer to the true order of the death times 
than the IPI (0.65), R- IPI (0.63), and NCCN- IPI (0.67) 
risk groups (Table 3). Furthermore, the lowest IBS was 
achieved with the CPH model (IBS 0.149), suggesting 
that the predicted survival curves of this model were sig-
nificantly closer to observed outcome (deaths) than the 
Kaplan–Meier curves corresponding to the IPI (0.169), 
R- IPI (0.172), and NCCN- IPI (0.164) risk groups (Table 3). 
The time- varying AUC plot shows that for each time t, 
the CPH model was superior to the IPI(- like) models for 
discriminating correctly between dead and alive patients. 
Thus, the CPH model was associated with larger AUC 
Table 1. Clinical characteristics of Swedish and Danish patients with 
diffuse large cell B- cell lymphoma.
Denmark (n = 2696) Sweden (n = 2167)
Median age, years 
 (range)
67 (18–95) 67 (18–95)
Sex ratio (M/F) 1.29 1.33
Ann Arbor stage, n (%)
I 527 (19.6) 443 (20.4)
II 481 (17.8) 586 (27.0)
III 587 (21.8) 405 (18.6)
IV 1101 (40.8) 733 (33.8)
ECOG performance status, n (%)
0 1320 (49.0) 1068 (49.2)
I 921 (34.2) 758 (35.0)
II 249 (9.2) 188 (8.7)
III 143 (5.3) 122 (5.6)
IV 63 (2.3) 31 (1.4)
Median number of 
extranodal sites, 
(range)1
1 (0–10) 0 (0–6)
Normalized LDH
>1, n (%) 1473 (54.6) 1309 (60.4)
Median 1.06 1.14
1The Danish lymphoma registry includes more extranodal sites than the 
Swedish Lymphoma Registry.
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values than the IPI(- like) indices (Fig. 2). The three per-
formance measures (C- index, IBS, and AUC) consistently 
pointed to the CPH model as the most accurate prognostic 
model, the R- IPI and IPI models the least accurate models, 
and the NCCN- IPI was in- between the two extremes. The 
prognostic performance of the IPI and NCCN- IPI scores 
(not risk groups) was also inspected. Using raw scores 
performed better than risk groups but was still inferior 
to the CPH model (Table 3 and Fig. 2). The performance 
and performance ranking of the different models was fully 
reproducible in the Swedish cohort (Table 3 and Fig. 2) 
and could confirm the prognostic superiority of the CPH 
model.
The performance, measured by the IBS and C- index, 
of the CPH models with one dichotomized variable was 
essentially on par with the CPH model without dichoto-
mized variables except when dichotomizing age (Table 3).
The PPV of the CPH model was 0.63 in the Danish 
cohort and 0.62 in the Swedish cohort. This indicates 
that in the group of patients predicted to have ≥50% 
risk of dying within 2 years by the CPH model, the per-
centage of observed events (deaths) was in fact above 
50%. In comparison, the PPVs of the high- risk groups 
defined by the IPI (DK: 0.48; SE: 0.46), the R- IPI (0.38; 
0.37), and the NCCN- IPI (0.57; 0.55) indicated that, except 
for the NCCN- IPI, the 2- year survival remained above 
50% in the high- risk groups.
The difference between modeling approaches is illus-
trated by plotting CPH- specific survival curves within each 
of the NCCN- IPI risk group (Fig. 3). For illustrational 
purposes, the plots only show the survival curves of 250 
randomly selected Danish patients. Note the significant 
Figure 1. Estimated survival probability over the first 7.5 years postdiagnosis shown as Kaplan–Meier curves for the different risk groups defined by 
the International Prognostic Index (IPI), Revised IPI (R- IPI), and National Comprehensive Cancer Network IPI (NCCN- IPI). The estimates from the Danish 
and Swedish cohorts are shown in the upper and lower plots, respectively.
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Table 2. Coefficients of the multivariate Cox proportional hazards mod-
el (estimated by using the Danish cohort).
HR
Lower 95% 
confidence limit
Upper 95% 
confidence limit
Age 1.06 1.05 1.07
ECOG performance status
0 1 (ref) – –
I 1.47 1.25 1.72
II 1.97 1.59 2.45
III 2.62 2.04 3.37
IV 3.25 2.32 4.54
Log(LDH) 1.36 1.24 1.50
Number of 
extranodal 
sites
1.08 1.02 1.15
Ann Arbor stage
I 1 (ref) – –
II 1.15 0.89 1.48
III 1.44 1.14 1.82
IV 1.37 1.09 1.73
Table 3. The integrated Brier score and C- index of the multivariate Cox 
proportional hazards (CPH) model, the International Prognostic Index 
(IPI) grouping, IPI scores, the National Comprehensive Cancer Network 
(NCCN- IPI) grouping, NCCN- IPI score, the revised IPI (R- IPI) grouping, 
and CPH models in which one variable used the IPI dichotomization.
Denmark Sweden
IBS C- Index IBS C- Index
CPH model 0.149 0.73 0.149 0.73
IPI 0.169 0.65 0.171 0.65
R- IPI 0.172 0.63 0.172 0.63
NCCN 0.164 0.67 0.164 0.67
IPI- score 0.168 0.66 0.166 0.66
NCCN- IPI- 
score
0.159 0.69 0.158 0.69
In the Danish data, these were measured using 10- fold cross validation. 
In the Swedish data, similar measures were obtained using the CPH 
model fitted on the Danish data.
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spread of survival curves predicted by the CPH model 
within the NCCN- IPI- specific risk groups, emphasizing 
the potential problems associated with group- based out-
come predictions (IPI, R- IPI, and NCCN- IPI) for individual 
patients.
Since models similar to the CPH model are character-
ized by higher complexity, precluding use without dedicated 
web- interfaces, we developed lymphomapredictor.org. On 
this page, users can test the CPH model versus the con-
ventional IPI, R- IPI, and NCCN- IPI models. The website 
was programmed using the “shiny” package and allows 
users to enter patient characteristics [23]. Furthermore, 
to facilitate interpretation, we also provide the survival 
of an age- gender matched background population of the 
Nordic countries [24].
Discussion
Using population- based lymphoma databases, we were 
able to evaluate and compare the original IPI to recently 
proposed variations, the R- IPI and the NCCN- IPI. In 
addition, and more importantly, we were able to show 
Figure 2. Time- varying area under the curve (AUC) of Cox proportional hazards (CPH) model and the International Prognostic Index (IPI) grouping, IPI 
score, National Comprehensive Cancer Network IPI (NCCN- IPI) grouping, NCCN- IPI score, and Revised IPI (R- IPI) grouping, combined with the Kaplan–
Meier estimator. These were estimated using repeated 10- fold cross validation in the Danish cohort, and the Swedish cohort was used as validation data.
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Figure 3. Predicted survival of 250 randomly selected patients in the Danish cohort predicted by the Cox proportional hazards model (CPH) and the 
Kaplan–Meier method for each National Comprehensive Cancer Network International Prognostic Index (NCCN- IPI) group. There is a notable spread 
of predicted survival within each risk group and a certain overlap of estimated survival curves between the risk groups.
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a substantial gain in prognostic accuracy by assuming 
linearity for the effects of continuous variables and using 
survival probability to predict outcome instead of dichoto-
mized variables and predefined risk groups.
Our results indicate that the IPI outperformed the R- IPI 
with small margins for each of the summary measures 
presented. Thus, simply regrouping the same risk factors 
into other risk groups did not lead to an increased pre-
dictive accuracy of the R- IPI over the IPI. However, we 
did see a significant benefit of using incremental scores 
for increasing values of continuous risk factors as proposed 
in the NCCN- IPI [9]. Using this approach, the NCCN- IPI 
was capable of providing better risk stratification than 
both the R- IPI and IPI, which underscores that substantial 
improvements in predictive accuracy are obtained by 
models that include more than two categories for risk 
factors. Furthermore, the performance of both the IPI 
and NCCN- IPI can be improved using the scores instead 
of the risk groups to rank patients. Taking this approach 
a step further, we developed a CPH model that was based 
on the exact same variables as the IPI, but without dichoto-
mization or the use of a few risk groups as outcome. 
This model assigned increased risk for each incremental 
values of age, Ann Arbor stage, normalized LDH ratio, 
number of extranodal sites, and ECOG performance score. 
When this model was tested against the NCCN- IPI, IPI, 
and R- IPI using appropriate statistical performance tests 
such as the Brier score, time- varying AUC, and C- index, 
the CPH model outperformed the other models. This 
finding clearly indicates that current models fail to exploit 
the full potential of available clinical data. The performance 
tests yielded similar results in the Swedish DLBCL popu-
lation, which indicates that these results are generalizable 
to other countries.
To investigate the causes of loss in predictive power 
also models including one dichotomized variable, dichoto-
mized as in the IPI- score, were fitted. The performance 
measures indicated that dichotomizing age leads to large 
losses in predictive performance. The dichotomization of 
the other variables did not cause major losses in predic-
tive performance. This highlights the importance of age 
as a prognostic factor for overall survival. Given that 
dichotomization only explained part of the information 
loss in the IPI- like models, we can conclude that also 
assigning the dichotomized variables the same weight in 
the final risk scores as well as grouping patients into risk 
groups instead of providing continuous risk scores cause 
large losses in prognostic performance.
Meaningful clinical risk scores should identify patients 
likely to fail standard therapy. In Zhou et al. focus was 
on finding a patient subgroup with a 5- year survival below 
50% [9]. Since long- term survival is strongly influenced 
by deaths due to old- age, we focused on discovering a 
subgroup with a 2- year, instead of 5- year, OS below 50%. 
The relatively high PPV for patients predicted to have a 
2- year OS below 50% confirmed that the CPH model 
was highly capable of identifying patients with poor sur-
vival and for whom experimental therapies or alternative 
treatment approached may be relevant. The 2- year OS of 
high- risk groups according to the R- IPI and IPI and 
associated PPV showed that these widely used models 
were unable to discover a meaningful high- risk group 
unlike the NCCN- IPI and the CPH model.
Within the risk groups defined by the best conventional 
model, the NCCN- IPI, we observed a large spread in the 
predicted survival (Fig. 3). This visualizes the interpreta-
tional problems clinicians have to deal with when group- 
based risk models are used for individual patient assessment. 
The CPH model became closer individualized outcome 
prediction by not forcing patients into few predefined 
risk groups. Furthermore, there was substantial overlap 
between survival predictions of patients in adjacent NCCN- 
IPI risk groups (Fig. 3). Both these observations indicated 
that risk groups based on dichotomized covariates led to 
a substantial loss of prognostic information.
Maurer et al. (2016) reported similar effects using event- 
free survival (EFS) at 24 months as endpoint. The EFS 
at 24 months was chosen since, in other studies, DLBCL 
survival normalized relative to that of a matched back-
ground population at this milestone time point [25–27]. 
Maurer et al. (2016) used a logistic regression model with 
continuous variables to calculate the probability of EFS 
at 24 months and compared the regression model to the 
IPI model [25]. Consistent with our finding, a large spread 
of predicted probabilities within each of the IPI groups 
was noted [25]. However, the logistic regression model 
also included clinical variables that are not part of the 
IPI (bulky disease, absolute lymphocyte count, and sex). 
Furthermore, IPI was developed as a general prognostic 
model and not for predicting 2- year EFS [6]. Thus, dif-
ferences in predictive performance of the logistic regression 
model presented by the authors and the original IPI are 
not explained only by avoiding dichotomizing the vari-
ables and using risk groups instead of continuous risk 
scores.
The purpose of this study was to compare the predic-
tive performance of simple clinical scores with a model 
using the same covariates. To keep the exposition simple, 
only a model with linear effects was reported (the CPH 
model). Tests with nonlinear covariate effects, in particular 
spline effects, did not lead to noticeable improvements 
in the prognostic performance (data not shown). We do 
not expect the presented CPH model to make IPI- like 
models obsolete, but our intention was to show how 
simple clinical data used in slightly more sophisticated 
ways can improve predictive accuracy substantially and 
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be of high value even in the era of molecular genetics. 
This is relevant, in particular, because testing for molecular 
high- risk disease may not be available to all clinicians in 
all parts of the world. Finally, while molecular genetics 
is becoming of utmost importance for risk profiling in 
DLBCL, we should be aware that clinical and genetic risk 
factors frequently overlap; double/triple hit DLBCL cases 
are often featured by disseminated extranodal involvement, 
which in itself is associated with poorer outcomes 
[28–30].
Further refinements of clinical risk models could be 
achieved by increasing the number of clinical variables 
included. For example, albumin concentration and the 
site of extranodal involvement may add prognostic value 
[8, 31]. Additionally, refinements of the IPI and NCCN- 
IPI have led to adjusted risk scores for the elderly [6, 
32], which indicate the importance of interaction effects. 
Furthermore, the effect of age and other continuous vari-
ables is likely to be nonlinear and the proportional hazards 
assumption of the CPH model is likely violated [9, 33]. 
However, in predictive modeling, unlike in classical infer-
ence about the covariate effects, model selection by extensive 
assumption checking can be fairly replaced using the 
generalization/prediction error as model selection criterion 
[34]. Future research will focus on using different model 
formulations and more variables to further enhance out-
come prediction from clinical data. To accomplish this 
task, different flexible modeling approaches such as spline 
models and random survival forests may be useful [35, 
36]. The main drawback of complex survival models is 
a need for dedicated software for implementation in rou-
tine clinical setting. However, since most physicians have 
mobile devices available this limitation is easily overcome 
today. Our CPH model was implemented in the form of 
an interactive web page (lymphomapredictor.org), where 
clinicians can test it against conventional models.
Similar to IPI- like models, the CPH model classifies a 
relatively large proportion of patients to be at intermedi-
ate risk of dying within 2 years. Even though future 
modeling efforts might lead to further model improve-
ments, patients at intermediate risk (≈50%) will likely 
still exist. These groups are clinically challenging, as risk 
estimates around 50% equal tossing a coin. However, 
uncertainties like these arise, at least in part, from many 
unknown factors that may not be related to DLBCL. These 
include deaths from other causes, which are particularly 
relevant in a disease of old age like DLBCL. Using cause- 
specific survival and disease- free survival as end- points 
may avoid this issue, but we were not able to provide 
these end- point due to the structure of databases used 
in the study. Other reasons may be the fact that use of 
baseline information will not be able to predict future 
events with 100% accuracy. Patients’ decisions regarding 
treatment and serious adverse events and complications 
to treatments between diagnosis and the time of interest 
are factors that influence survival but cannot be captured 
by baseline clinicopathologic features.
A drawback of the used registers is the risk of incorrect 
disease classification. In particular, primary mediastinal 
B- cell lymphoma (PMBCL) cases could have been regis-
tered as DLBCL to some extent. The outlook for PMBCL 
patients tends to be better than in DLBCL, but given the 
rarity of PMBCL as compared to DLBCL potential biases 
arising from this small group are likely to be insignificant 
[32].
In conclusion, we hope that future developments in 
statistics and machine learning will allow exhaustive use 
of the information available in our large clinical databases 
and pave the path toward personalized medicine based 
on a combination of clinical data and molecular genetics 
rather than the latter alone.
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